The huayin medical equipment is the latest to make its way into China’s medical supplies market.
The company is the largest supplier of acupuncture needles and related equipment in the country, according to an annual report released by the Central Commission for Discipline Inspection (CCDI) last week.
The huayan needles are designed to deliver needles directly to the patient’s nose, but the company also offers them to users who need them in the workplace or to treat infections.
The company has more than 700 stores across China and has received a lot of press in recent years for selling the needles.
In November last year, a man was hospitalized after using a huayn to remove an infected cut on his head.
The doctor and an ambulance crew rushed to the hospital and the man recovered, but a doctor had to cut his nose off after he was unable to reach the wound.
A few months earlier, a woman who had a blood infection in her nose contracted pneumonia in the hospital, where she had been using the needles to treat a viral infection in the same area.
The CCDI said the company was the first to make a profit from a medical device since 2011, when the company first made an initial investment.
Huayin said the firm had already received a number of orders from healthcare organizations to supply needles to Chinese hospitals.
The firm said the sales of the needles have already surpassed 10 million yuan ($130,000), but that the supply of the equipment has been slow and that its growth was not yet steady.
Huayan said it has had no problem making profits from its business and that the company had already been in talks with a number in the Chinese healthcare industry about partnering with the Chinese company.
It has been difficult to find a distributor for the needles, however, because the company has not been able to get a contract from hospitals and health care organizations in China, Huayin chief executive Wang Huo said.
Huayon said it plans to sell the needles at its Chinese stores and on its website in the coming months.
The company plans to make it available for sale at several Chinese hospitals in the next few months, the report said.